반려동물용 의약품 시장 : 제품 유형별, 적응증별, 동물 유형별, 유통 채널별 - 세계 예측(2025-2030년)

The Companion Animal Pharmaceuticals Market was valued at USD 14.39 billion in 2023, expected to reach USD 15.28 billion in 2024, and is projected to grow at a CAGR of 6.67%, to USD 22.62 billion by 2030.

The companion animal pharmaceuticals market encompasses drugs and medications designed specifically for pets, including dogs, cats, and other domesticated animals, addressing medical needs such as pain management, vaccination, anti-infectives, vaccines, parasiticides, and dermatological treatments. This sector is increasingly vital as pet ownership rises globally, driven by humanization trends where pets are viewed as family members, alongside concerns for animal health and wellness. Demand is propelled by advancing veterinary medicine, growing awareness of pet healthcare, and increased spending capability on pet-related services. The accessible market extends across veterinary clinics, home pharmacies, and online sales platforms. Key growth influencers include the increase in pet adoption rates, burgeoning veterinary infrastructure, technological advancements in drug formulations, and proliferation of chronic pet diseases. Opportunities arise from developing oral alternatives to injections, personalized medicine tailored to individual animals, and growth in emerging markets with rising pet adoption rates. However, market growth faces obstacles such as high cost of pharmaceuticals, stringent regulatory requirements for drug approval, and potential side effects of medications that could deter adoption. Economic slowdown impacts spending on pet healthcare, further challenging market expansion. Innovation can pivot around the development of eco-friendly, safe, and cost-effective medications, and leveraging biotechnology for novel therapeutics. Collaborative research between pharmaceuticals and veterinary institutions might offer breakthroughs in treatment efficacy and safety. Trending interest in therapeutic nutrition and wellness products supplementary to pharmaceuticals can also drive market exploration. The market is competitive and dynamic, characterized by rapid technological advancements and shifts in pet owner preferences, necessitating real-time market analysis and adaptive strategies to address demographic changes and evolving consumer needs. Companies successful in marrying innovation with consumer demand are poised to capture significant market share.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Companion Animal Pharmaceuticals Market

The Companion Animal Pharmaceuticals Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing Prevalence of Zoonotic and Chronic Diseases
  • Rising Number of Companion Animals and Awareness About their Hygiene
  • Increasing Awareness and Expenditure Among People Regarding Animal Healthcare
• Market Restraints
  • Several Risk Factors Associated with Companion Animal Health APIs
• Market Opportunities
  • Development of New Drugs and Vaccines for Companion Animal
  • Strategic Collaborations Along with Emergence of Market Players Across the Developing Economies
• Market Challenges
  • Stringent Regulations Associated with the Approval for Drugs

Porter's Five Forces: A Strategic Tool for Navigating the Companion Animal Pharmaceuticals Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Companion Animal Pharmaceuticals Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Companion Animal Pharmaceuticals Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Companion Animal Pharmaceuticals Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Companion Animal Pharmaceuticals Market

A detailed market share analysis in the Companion Animal Pharmaceuticals Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Companion Animal Pharmaceuticals Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Companion Animal Pharmaceuticals Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Companion Animal Pharmaceuticals Market, highlighting leading vendors and their innovative profiles. These include Phibro Animal Health Corporation, Hipra Laboratories, S.A., Vetneeds Group, Neogen Corporation, Norbrook Laboratories Ltd., Tianjin Ringpu Biotechnology Co., Ltd., Stanex Drugs and Chemicals Pvt Ltd., Indian Immunologicals Ltd., Alivira Animal Health Limited, Kyoritsu Seiyaku Corporation, Dechra Pharmaceuticals PLC, Elanco Animal Health Incorporated, SkyEc Pharmaceuticals Private Limited, Endovac Animal Health, LLC, Lutim Pharma Pvt. Ltd., Virbac S.A., Ceva Sante Animale, Meiji Group, Boehringer Ingelheim International GmbH, Century Pharmaceuticals Ltd., Zydus Animal Health, Vetbiolix, Merck & Co. Inc., Veko Care, Ashish Life Science Pvt. Ltd., Chanelle Pharma, Zoetis Inc., Hester Biosciences Limited, Orion Corporation, and Eco Animal Health Group PLC.

Market Segmentation & Coverage

This research report categorizes the Companion Animal Pharmaceuticals Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Analgesics, Anti-infectives, Anti-inflammatory, Medicated Feed Additives, Parasiticides, and Vaccines.
• Based on Indication, market is studied across Behavioral Disorders, Dermatologic Diseases, Infectious Diseases, Orthopedic Diseases, and Pain.
• Based on Animal Type, market is studied across Cats, Dogs, and Horses.
• Based on Distribution Channel, market is studied across Online Pharmacies, Retail Pharmacies, Veterinary Clinics, and Veterinary Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing Prevalence of Zoonotic and Chronic Diseases
    • 5.1.1.2. Rising Number of Companion Animals and Awareness About their Hygiene
    • 5.1.1.3. Increasing Awareness and Expenditure Among People Regarding Animal Healthcare
  • 5.1.2. Restraints
    • 5.1.2.1. Several Risk Factors Associated with Companion Animal Health APIs
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of New Drugs and Vaccines for Companion Animal
    • 5.1.3.2. Strategic Collaborations Along with Emergence of Market Players Across the Developing Economies
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent Regulations Associated with the Approval for Drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Diverse range of analgesics to treat general and chronic pain in companion animals
  • 5.2.2. Indication: Rising focus on developing advanced pharmaceuticals for antimicrobial resistance and infectious diseases in companion animals
  • 5.2.3. Animal Type: Increased adoption of dogs as companion animals and rising expenditure on their treatments
  • 5.2.4. Distribution Channel: Enhanced accessibility and convenience of attaining companion animal pharmaceuticals through online channels
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. Companion Animal Pharmaceuticals Market, by Product

• 6.1. Introduction
• 6.2. Analgesics
• 6.3. Anti-infectives
• 6.4. Anti-inflammatory
• 6.5. Medicated Feed Additives
• 6.6. Parasiticides
• 6.7. Vaccines

7. Companion Animal Pharmaceuticals Market, by Indication

• 7.1. Introduction
• 7.2. Behavioral Disorders
• 7.3. Dermatologic Diseases
• 7.4. Infectious Diseases
• 7.5. Orthopedic Diseases
• 7.6. Pain

8. Companion Animal Pharmaceuticals Market, by Animal Type

• 8.1. Introduction
• 8.2. Cats
• 8.3. Dogs
• 8.4. Horses

9. Companion Animal Pharmaceuticals Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Online Pharmacies
• 9.3. Retail Pharmacies
• 9.4. Veterinary Clinics
• 9.5. Veterinary Hospitals

10. Americas Companion Animal Pharmaceuticals Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Companion Animal Pharmaceuticals Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Companion Animal Pharmaceuticals Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Boehringer Ingelheim Introduces NexGard SPECTRA in India, a New Chewable Solution for Comprehensive Dog Parasite Protection
  • 13.3.2. Zoetis Receives FDA Approval for Groundbreaking Canine Osteoarthritis and Allergy Treatments
  • 13.3.3. Akston Biosciences Shifts Focus to Pet Health, Using Cutting-Edge Technology to Develop New Treatments
  • 13.3.4. Zoetis Expands Global Reach with Acquisition of Jurox, Enhancing Veterinary Medication Portfolio for Companion and Livestock Care

Companies Mentioned

• 1. Phibro Animal Health Corporation
• 2. Hipra Laboratories, S.A.
• 3. Vetneeds Group
• 4. Neogen Corporation
• 5. Norbrook Laboratories Ltd.
• 6. Tianjin Ringpu Biotechnology Co., Ltd.
• 7. Stanex Drugs and Chemicals Pvt Ltd.
• 8. Indian Immunologicals Ltd.
• 9. Alivira Animal Health Limited
• 10. Kyoritsu Seiyaku Corporation
• 11. Dechra Pharmaceuticals PLC
• 12. Elanco Animal Health Incorporated
• 13. SkyEc Pharmaceuticals Private Limited
• 14. Endovac Animal Health, LLC
• 15. Lutim Pharma Pvt. Ltd.
• 16. Virbac S.A.
• 17. Ceva Sante Animale
• 18. Meiji Group
• 19. Boehringer Ingelheim International GmbH
• 20. Century Pharmaceuticals Ltd.
• 21. Zydus Animal Health
• 22. Vetbiolix
• 23. Merck & Co. Inc.
• 24. Veko Care
• 25. Ashish Life Science Pvt. Ltd.
• 26. Chanelle Pharma
• 27. Zoetis Inc.
• 28. Hester Biosciences Limited
• 29. Orion Corporation
• 30. Eco Animal Health Group PLC